Personalized Therapy in the Era of Precision Medicine: Guidance on Histology-Agnostic Therapies for the Community Multidisciplinary Oncology Team

Experts discuss histology-agnostic therapies for solid tumors, including key efficacy and safety data and guidance on appropriate molecular testing and adverse event management with an on-demand webcast and downloadable slideset from a live workshop series.

Share

Program Content

Activities

Histology-Agnostic Biomarkers in Solid Tumors
Personalized Therapy in the Era of Precision Medicine: Guidance on Histology-Agnostic Therapies for the Community Multidisciplinary Oncology Team
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 19, 2023

Activities

Histology-Agnostic Therapies
Personalized Therapy in the Era of Precision Medicine: Guidance on Histology-Agnostic Therapies for the Community Multidisciplinary Oncology Team
Video
Congratulations: You achieved a completion on 04/09/2022

Released: October 04, 2023

Expires: October 03, 2024

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from Bayer HealthCare Pharmaceuticals Inc., Elevation Oncology, Merck Sharp & Dohme Corp., and Merus NV.

Bayer HealthCare Pharmaceuticals Inc.

Elevation Oncology

Merck Sharp & Dohme Corp.

Merus NV